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Abstract: Serotonin (5-HT) regulates important biological and psychological processes 
 including mood, and may be associated with the development of several psychiatric disorders. 
An  association between psychopathology and genes that regulate 5-HT neurotransmission is a 
robust area of research. Identification of the genes responsible for the predisposition,  development, 
and pharmacological response of various psychiatric disorders is crucial to the advancement of 
our understanding of their underlying neurobiology. This review highlights research investigating 
5-HT transporter (5-HTTLPR) polymorphism, because studies i nvestigating the impact of the 
5-HTTLPR polymorphism have demonstrated significant associations with many psychiatric 
disorders. Decreased transcriptional activity of the S allele (“risk allele”) may be associated with 
a heightened amygdala response leading to anxiety-related personality traits, major depressive 
disorder, suicide attempts, and bipolar disorder. By contrast, increased transcriptional activity 
of the L allele is considered protective for depression but is also associated with completed 
suicide, nicotine dependence, and attention deficit hyperactivity disorder. For some disorders, 
such as post-traumatic stress disorder and major depressive disorder, the research suggests 
that treatment response may vary by allele (such as an enhanced response to serotonin specific 
reuptake inhibitors in patients with major depressive disorder and post-traumatic stress disorder 
with L alleles), and for alcohol dependence, the association and treatment for S or L alleles 
may vary with alcoholic subtype. While some studies suggest that 5-HTTLPR polymorphism 
can moderate the response to pharmacotherapy, the association between 5-HTTLPR alleles and 
therapeutic outcomes is inconsistent. The discovery of triallelic 5-HTTLPR alleles (L
A
/L
G
/S) 
may help to explain some of the conflicting results of many past association studies, while 
concurrently providing more meaningful data in the future. Studies assessing 5-HTTLPR as 
the solitary genetic factor contributing to the etiology of psychiatric disorders continue to face 
the challenges of statistically small effect sizes and limited replication.
Keywords: 5-HTTLPR, SCC6A4, 5-HT, serotonin, genetics, alleles, triallele, psychiatric, 
polymorphisms, pharmacotherapy, psychopathology
Introduction
Serotonin (5-hydroxytryptamine, 5-HT), is a monoamine neurotransmitter that  regulates 
numerous important physiological processes, including sleep, food intake, pain, 
 vascular tone, platelet function, and motor activity.1,2 However, 5-HT is perhaps best 
known for its mood and behavior modulating effects within the central nervous  system. 
Consequently, 5-HT has been implicated in the pathology of numerous  psychiatric 
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disorders and has been a primary focus in the treatment of 
such diseases. The growing understanding of genetics has led 
to an increasing association between the genes that regulate 
5-HT neurotransmission and the psychiatric disorders that 
have been characterized by 5-HT dysregulation.3
In humans, 5-HT is synthesized from the amino acid 
tryptophan via a two-step process.1,2 Because 5-HT itself 
is unable to cross the blood–brain barrier, tryptophan is 
moved into the central nervous system by a transport protein, 
where it is subsequently converted to 5-HT by the enzymes 
tryptophan hydroxylase and amino acid decarboxylase.2 
After  biosynthesis, 5-HT is packaged into presynaptic 
vesicles in the axon terminal for storage and protection 
from metabolism.1,2
Following depolarization, 5-HT is released where it 
can bind to either a postsynaptic 5-HT receptor to induce 
potentiation or a presynaptic autoreceptor to induce feedback 
inhibition of further 5-HT release.1 Seven families of 5-HT 
receptors have been identified, 5-HT
1
 through 5-HT
7
, all of 
which are G protein-coupled receptors with the exception of 
5-HT
3
.1,2 Currently, there are 14 unique 5-HT receptor sub-
types, some with known but varied function.2 While specific 
receptor subtypes are associated with certain functions, such 
as 5-HT
1D
 and cranial blood vessel vasoconstriction,1 the 
complexity of the central nervous system is such that 5-HT 
is able to elicit a wide variety of physiological responses 
through particular combinations of receptor subtypes, brain 
areas, and involved neurons.2
Released 5-HT remains in the synaptic space until it is 
either reaccumulated into the presynaptic neuron or metabo-
lized by monoamine oxidase. The serotonin transporter 
protein (5-HTT), a transporter located on the presynaptic 
neuron, is responsible for reuptake of the neurotransmitter 
and represents the primary mechanism for termination of 
serotonergic neurotransmission.2 Reaccumulated 5-HT is 
repackaged into synaptic vesicles and reused.1,2 Any 5-HT 
that escapes reuptake by 5-HTT is inactivated by monoamine 
oxidase, and while both processes occur simultaneously, it 
is reuptake by 5-HTT that is primarily responsible for ter-
minating the action of 5-HT.2 By this mechanism, 5-HTT is 
able to regulate the concentration of 5-HT in the synapse, 
thereby controlling the magnitude and duration of postsynap-
tic signaling.1,4 The genes that code for 5HTT, solute carrier 
family 6 neurotransmitter transporter, serotonin, member 4 
(SLC6A4), and polymorphic variants, have become the most 
investigated in psychiatry, psychology, and neuroscience.5
A polymorphism is a genetic variation in a segment 
of DNA that occurs in a population at a frequency greater 
than 1%, resulting in the existence of multiple alleles or ver-
sions of a given gene which may be present at a locus on a 
specific chromosome.5 Alleles determine distinct traits, such 
as eye color. For example, a polymorphism may result in the 
existence of alleles A and B, or more, of which either may be 
present at a gene locus of the two chromosomes. Each allele is 
associated with differing functionality; hence, polymorphisms 
can alter the expression or activity of the gene in which they 
occur.5 Polymorphisms in SLC6A4 can significantly affect 
regulation of serotonergic neurotransmission. Expression 
of a gene is controlled by the promoter, a regulatory region 
located upstream of the protein coding region that allows RNA 
polymerase to bind and initiate transcription.  Polymorphisms 
in the promoter region of the gene encoding 5-HTT have 
been associated with varying degrees of transcriptional activ-
ity, which leads to varying degrees of RNA synthesis and 
protein formation.4 SLC6A4 is located on chromosome 17 
(17q11.1–q12) and contains a functional insertion-deletion 
polymorphism of two 22-base pair repeat elements in the 
promoter region, known as the 5-HTT gene-linked promoter 
region (5-HTTLPR). This functional polymorphism results 
in two possible primary allelic variations of differing length 
and activity, ie, a long (L) allele consisting of 16 repeats and 
a short (S) allele consisting of 14 repeats.4,6–8 Because humans 
have two copies of each chromosome, genotype combina-
tions can include S-homozygous (S/S), S/L heterozygous, 
or L-homozygous (L/L). Cells homozygous for the L allele 
(L/L) have been shown to produce levels of 5-HTT mRNA 
1.4 to 1.7 times greater than that seen in cells containing the 
S allele.4 Moreover, the L/L variant was capable of removing 
5-HT from the synaptic cleft at a rate 1.9–2.2 times greater 
than the S/S and S/L variants. Hence, the L-homozygous 
variant is associated with increased transcriptional activity of 
the 5-HTT promoter, resulting in increased 5-HTT expres-
sion and 5-HT reuptake from the synapse relative to that of 
S-containing variants.
In addition to the L/S alleles, many other genetic 
 variations have been identified for the 5-HTT (SLC6 A4) 
gene. Several single nucleotide polymorphisms that can 
change the activity of 5-HTT have been identified. One single 
nucleotide polymorphism that is particularly relevant is an 
adenine to guanine single nucleotide polymorphism that 
occurs only in the long allele, resulting in its division into 
two distinct alleles, ie, L
A
 and L
G
. Evidence suggests that the 
L
G
 allele may have transcriptional activity similar to that of 
the S allele, while only the L
A
 allele increases transcriptional 
activity.9,10 This single nucleotide polymorphism has not 
been considered in many studies, and hence assessment of 
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the significance and association of the L
A
 and L
G
 alleles is 
limited at this time. However, it is probable that the existence 
of the triallelic alleles, not known until recently, has resulted 
in an underestimation of the statistical and clinical effect of 
5-HTTLPR.11
Studies of the association between the 5-HTTLPR variant 
and psychiatric disorders have often produced inconsistent 
results.11,12 However, for many disorders, evidence for a 
variant effect does exist, often with significant implica-
tions for treatment. The aim of this review is to present the 
current understanding of the 5-HTTLPR within the frame-
work of psychopathology and when available, potential 
 pharmacotherapy implications.
5-HTT variants: psychopathology 
and pharmacotherapy implications
The heritability of many psychiatric disorders is well known 
and widely accepted. However, pursuit of the specific genes 
responsible for the transmission of these diseases has been 
limited due to the relative novelty, cost, and complexity of 
human behavior. Since its discovery in the mid 1990s,13,14 
5-HTTLPR has received increasing attention as a risk factor 
for various psychiatric disorders4 and represents an attrac-
tive and heavily researched target for psychiatric genetic 
research (see Table 1). While both 5-HTTLPR alleles are 
regarded as functional, it is hypothesized that specific variants 
increase an individual’s susceptibility to specific psychiatric 
disorders.4,7,8,11 Furthermore, as is the case in other fields of 
medicine (eg, oncology),15 genotype can be an important 
factor in pharmacotherapy. Thus, knowledge of genetics can 
direct and optimize treatment modalities.
Though this is not a critical review, a search of  current 
studies was performed in PubMed and from other  references 
in the published studies using the terms: 5-HTTLPR, 
 serotonin transporter, major depressive disorder or 
 depression, anxiety, suicide, bipolar disorder, alcoholism 
or  alcohol dependence, nicotine dependence and  smoking, 
post traumatic stress disorder, and attention def icit 
 hyperactivity disorder. Notably, we decided not to include 
schizophrenia in this review because the broad spectrum of 
 psychopathology presented by this illness was impossible 
to address in this review.
Anxiety
The heritability of anxiety-related personality traits is 
believed to be between 40% and 60%, but the genes respon-
sible have yet to be identified, and heritability involves 
multiple genes.4 Within the serotonergic treatment model 
of anxiety, the 5-HTT is a frequent target of anxiolytic 
pharmacotherapy,16 and has been implicated in the pathology 
of anxiety disorders in human and animal studies.4,6,17–19
In research on the association between 5-HTTLPR 
alleles and personality traits, carriers of S alleles (S/S or 
S/L) were reported to have higher neuroticism (consid-
ered a  vulnerability factor for anxiety and depression) 
scores than L homozygotes (L/L).4 Specifically, the S 
allele was significantly associated with the Revised-NEO 
 Personality  Inventory (NEO-PI-R) neuroticism facet of 
anxiety (P = 0.027) and the Cattell 16PF personality inven-
tory anxiety factor.4 Based on the heritability demonstrated 
in twin studies, the authors estimated that 5-HTT genotype 
contributes 3%–4% of total variation and 7%–9% of genetic 
variance in anxiety-related personality traits.4
Given the inherent difficulty and subjectivity in  measuring 
behavior and personality, a more objective  association 
between 5-HTT genotype and anxiety was sought using the 
endophenotype of amygdala activity, the core of the fear 
response.6 Studies had demonstrated an association between 
5-HTT functionality and an abnormal fear response, a condi-
tion that is dependent upon the amygdala.6 The researchers 
theorized that functional magnetic resonance imaging mea-
surement of amygdala activity in response to fearful stimuli 
would allow for more objective conclusions regarding the 
influence of 5-HTT genotype on fear and anxiety-related 
behavior.6 The results demonstrated that S carriers had a 
significantly greater amygdala response than participants 
with the L/L alleles, suggesting that the S allele is associated 
with a greater degree of amygdala excitability.6 Moreover, 
the 5-HTT-mediated effect on excitability was specific to 
the amygdala, because subjects did not exhibit significant 
differences in excitability of other brain regions,6 and is 
confirmed by others.17,18 Increased amygdala activity in S 
carriers was reported to be in response to aversive but not 
pleasurable pictures.17 Further, in an event-related functional 
magnetic resonance imaging study, in addition to amplitude 
of neural response, 5-HTT genotype also affected connectiv-
ity between components of the neural system.18
In a meta-analysis of 14 studies and three unpublished 
data sets, a significant association between the S allele and 
heightened amygdala activation was found (P , 0.001) and 
was estimated to account for as much as 10% of phenotypic 
variance.19 Thus, the increased fear and anxiety-related 
behavior associated with the S allele may be the result of an 
exaggerated amygdala response to aversive environmental 
stimuli, thereby predisposing carriers to stress-related psy-
chiatric disorders.19
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Table 1 Notable studies reporting the association of the 5-HTTLPR polymorphism to psychopathology
Psychopathology  Reference n Risk allele  Comment
Anxiety Lesch et al4 505 S Genotype contributes 3%–4% of total variation and 7%–9%  
of genetic variance in anxiety-related personality traits
Hariri et al6 28 S Increased amygdala activity in response to fearful stimuli
Heinz et al17 29 S Increased amygdala activity in response to aversive but not  
pleasant pictures
Surguladze et al18 29 S Genotype affects amplitude of neural response and  
connectivity within the neural system
Munafo et al19 NR S Meta-analysis; heightened amygdala activation; 10%  
of phenotypic variance
Munafo et al20 3872 NS Meta-analysis; no association with two measures of anxiety- 
related personality traits; results differ between personality  
inventories
Depression Caspi et al7 847 S G × E interaction with effect of stressful life events on  
depression risk; childhood maltreatment predicted adult  
depression in S carriers only
Risch et al12 14,250 NS Meta-analysis; no significant association with depression; no 
interaction with the effect of stressful life events on the risk 
of depression
Coplan et al27 9 S Bonnet macaques; elevated CRH in CSF of primate S  
carriers raised under stressful conditions
Yu et al29 121 L/L Better response to fluoxetine with L/L genotype; genotype  
predicted response; L homozygotes more likely to be  
responders
Smeraldi et al30 102 L L carriers demonstrated a greater response to fluvoxamine
Zanardi et al33 60 L/L Dose response: L/S genotype had response to paroxetine  
in between S and L homozygotes
Pollock et al34 95 L/L No genotype effect on response to nortriptyline; L/L  
genotype associated with quicker response to paroxetine
Durham et al35 206 L/L L/L genotype associated with quicker response to  
sertraline
Huezo-Diaz et al37 795 L The effect of 5-HTTLPR on response to escitalopram  
response was conditional on gender (males) and modulated 
by the rs2020933 polymorphism
Serretti et al39 1435 L/L Meta-analysis; poor response to SSRIs in S carriers; S allele- 
mediated effect on time-to-response; L/L genotype versus  
the L/S and S/S genotypes yielded significant odds ratios for  
response rate and response within four weeks
Karg et al26 40,749 S Meta-analysis; strong association between the 5-HTTLPR  
S allele and an increased risk of developing depression  
under stress. When specific stressors were considered, the 
strongest association was with the childhood maltreatment  
and the specific medical condition groups
Taylor et al40 5408 NS The 5-HTTLPR did not predict antidepressant outcome
Lewis et al36 258 took citalopram 
262 took reboxetine
NS No influence of 5-HTTLPR as a predictor of depression  
outcome
Suicidal behavior Du et al43,44 55 L Completed suicide victims had almost double the frequency 
of the L/L genotype than that of controls
Russ et al45 102 NS No significant difference in allele frequency; significantly  
increased hopelessness and suicidal ideation in patients  
homozygous for the L allele
Anguelova et al46 2539 S Meta-analysis; association attributable to studies  
investigating suicide attempters
Bipolar disorder Cho et al48 4296 + 587 trios S Meta-analysis, population-based and family-based; increased  
susceptibility to BPD
Anguelova et al49 3467 S Meta-analysis; increased susceptibility to BPD
Rotondo et al50 349 S Association significant only for BPD without comorbid  
panic disorder versus BPD with comorbid panic disorder
(Continued)
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Table 1 (Continued)
Psychopathology  Reference n Risk allele  Comment
Mundo et al52 56 S Association between S allele and manic/hypomanic episodes 
in BPD patients treated with antidepressants
PTSD Lee et al55 297 S Significantly higher frequency of the S-homozygous  
genotype in patients with PTSD
Wang et al56 388 S′/S′ The S′-homozygous genotype was associated with the  
PTSD severity score in the 228 participants who had  
combat severity data
Xie et al57 1252 S S carriers have increased risk of PTSD in response to  
trauma as a child and adult
Mushtaq et al59 330 L/L L-homozygous is associated with greater responsiveness of  
PTSD to sertraline (100 mg/day) with lower drop out due  
to adverse events
Grabe et al60 3045 LA Gene-dose effect; interaction between the LA allele and  
number of traumatic life events
Alcohol dependence Kweon et al64 346 L Increased risk of alcoholism; gene-dose effect; younger age  
of onset; associated with family history of AD
McHugh et al66 8050 S Meta-analysis; greater effect seen in S homozygotes
Ait-Daoud et al67 34 L L carriers had higher craving than S/S; Craving in L carriers  
increased with an earlier age of onset of problem drinking
Feinn et al69 5814 S S allele significantly associated with AD; Greatest  
association between S allele and comorbid psychiatric  
condition, early-onset or more severe AD subtype
Enoch et al70 547 NS No significant association for AD only; Frequency of S allele 
significantly increased in patients with AD and comorbid  
drug dependence
Matsushita et al8 967 S/S S-homozygous genotype associated with binge drinking
Kranzler et al75 101 TX Increased alcohol consumption in EOAs with fluoxetine
Pettinati et al76 100 NA Increased alcohol consumption in EOAs with sertraline;  
decreased consumption in LOAs
Kranzler et al77 134 L′/L´ In LA/LA (L′/L´) homozygotes, the effects of medication 
group varied by age of onset. LOAs with the L′/L´ alleles 
had fewer drinking and heavy drinking days with sertraline; 
EOAs had fewer drinking and heavy drinking days with 
placebo
Johnson et al78 271 NR Treatment with ondansetron increased the number and  
percentage of days abstinent in patients with EOA but not  
LOA
Kenna et al72 15 L/L L homozygotes receiving ondansetron had significantly  
fewer DDD than patients receiving sertraline
Johnson et al82 283 L/L L homozygotes who received ondansetron reported fewer  
mean drinks per drinking day and a higher percentage of  
days abstinent
Nicotine  
dependence
Kremer et al87 730 L Frequency significantly increased in both current and past  
smokers compared with nonsmoker controls
ADHD Thakur et al90 157 LA LA carriers responded significantly better to  
methylphenidate than placebo; patients without a LA allele  
did not exhibit a significantly better response compared  
with placebo
Seegar et al91 243 L/L Frequency of L-homozygous genotype significantly  
increased in patients with hyperkinetic disorder both with  
and without conduct disorder
Retz et al93 169 L/L L homozygotes scored significantly higher on the WURS.
Zoroğlu et al94 199 L Frequency of S-homozygous genotype significantly lower in  
patients with ADHD
Abbreviations: AD, alcohol dependence; ADHD, attention deficit hyperactivity disorder; BPD, bipolar disorder; CRH, corticotrophin-releasing hormone; CSF, cerebrospinal 
fluid; DDD, drinks per drinking day; EOA, early-onset alcoholism; G × E, gene × environment; L, long 5-HTTLPR allele; LOA, late-onset alcoholism; NR, not reported; NS, 
not significant; PTSD, post-traumatic stress disorder; S. short 5-HTTLPR allele; SSRI, selective serotonin reuptake inhibitor; WURS, Wender Utah Rating Scale; 5-HTT, 
serotonin transporter.
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While findings regarding the association between the 
5-HTTLPR and amygdala response have been rather con-
sistent, some studies assessing the association between 
5-HTTLPR and anxiety traits directly have produced mixed 
results. For example, Munafò et al20 confirmed data by Willis-
Owen et al21 that reported no association between 5-HTTLPR 
polymorphism and two measures of  anxiety-related per-
sonality traits, ie, harm avoidance and Eysenck Personality 
Questionnaire (EPQ) neuroticism.20 While a large number of 
small studies in support of an association exist, these stud-
ies primarily used the NEO-PI-R measure of  neuroticism. 
And while the combined EPQ and NEO-PI-R measures of 
neuroticism were significant for an association with the S 
allele, stratification by neuroticism measurement instru-
ment delineated only studies utilizing the NEO-PI-R to 
remain significant.20 The authors interpreted this as sug-
gestive of a variation in an anxiety-related personality trait 
defined by the NEO-PI-R instrument being influenced by 
the 5-HTTLPR.20
In summary, the bulk of the evidence suggests that 
increased serotonergic neurotransmission is associated with 
the S allele, which may be anxiogenic, as demonstrated by 
an enhanced amygdala response to anxiety. By contrast, 
studies of the direct association between 5-HTT genotype 
and anxiety traits have produced mixed results depending on 
the personality inventory utilized, suggesting that larger and 
more fully powered studies are necessary to provide more 
definitive evidence of this association.
Depression
While the annual prevalence of depression as defined by the 
Diagnostic and Statistical Manual IV-TR (DSM-IV-TR)22 
criteria is estimated to be 3.2%, the heritability of depression 
is thought to be 31%–42%.23 In 2003, a gene × environment 
(G × E) hypothesis was proposed, suggesting that because 
an association between 5-HTT genotype and response to 
stress in animals and humans had been demonstrated, and 
that stressful life events are known to affect the onset and 
course of depression,24 it was therefore logical to conclude 
that the 5-HTT genotype could contribute to the development 
of depression.7 These researchers sought to determine if 
5-HTT genotype altered the serotonergic response to stress, 
thereby predisposing participants to a greater influence of 
stressful life events on depression.7 Caspi et al demonstrated 
a positive association between the number of stressful life 
events and the probability of depression that was statistically 
stronger in S carriers than L homozygotes.7 This association 
suggested that among participants who experienced more 
than four stressful life events, S carriers were twice as likely 
as L homozygotes to develop depression. The authors also 
reported that maltreatment as a child predicted depression 
as an adult in S carriers only. While the researchers noted 
that their results did not prove a direct association between 
5-HTT genotype and depression, they concluded that S car-
riers were more likely to develop depression in response to 
stressful life events.7
In order to examine the association between 5-HTT 
genotype and depression, Risch et al12 performed a meta-
analysis of 14 replication studies (n = 14,250) and found 
that many of the trials failed to reproduce the results reported 
by Caspi et al.7 Furthermore, other studies reviewed were 
only able to replicate the results partially or even produced 
contradictory results.12 While this meta-analysis affirmed 
the association between number of stressful life events and 
depression, the study failed to find a significant association 
between 5-HTTLPR genotype and depression.12 Moreover, 
Risch et al12 failed to find a significant interaction between 
genotype and the effect of stressful life events on the risk 
of depression in men alone, women alone, or both genders 
combined.12 To test the G × E hypothesis more directly, 
the authors stratified the sample by number of stressful life 
events.12 Contrary to the results previously reported,7 they 
discovered no significant difference in allele frequency 
between those with and without depression,12 and noted that 
the largest increase in S allele frequency occurred for one 
stressful life event,12 inconsistent with the greater than four 
stressful life events as previously reported.7 Munafò et al25 
performed a similar G × E meta-analysis with five of 33 stud-
ies and concluded that the moderating effect of 5-HTTLPR 
on depression or interaction with significant life events was 
small or even negligible.
In contrast, a 2011 meta-analysis by Karg et al26 noted 
how, based on their a priori criteria, previous meta-analytic 
studies12,25 of the interaction between 5-HTTLPR polymor-
phism and stress in the development of depression excluded 
most publications. Karg et al included 54 of 56 studies 
by using a different data extraction approach.26 The main 
results of this meta-analysis demonstrated a strong associa-
tion between the 5-HTTLPR S allele and an increased risk 
of developing depression under stress. When the analysis 
was conducted considering specific stressors, the strongest 
association was with childhood maltreatment and the specific 
medical condition groups. Interestingly, Karg et al26 did 
not find such associations when they restricted the analysis 
to studies included in the previous meta-analyses.12,25 This 
suggests that the differences in results can be explained 
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with the significantly different number of studies included 
in the analysis.26
Caspi et al5 reviewed several lines of evidence examin-
ing the association between 5-HTTLPR and depression 
up until mid 2009 and assessed the G × E interaction and 
5-HTT stress sensitivity hypothesis specifically.5 In  analyzing 
the differences between studies producing positive and nega-
tive results, the authors suggest that the varying results may 
be related to the methodology by which stressful life events 
are assessed.5 Specifically, they concluded that: most of the 
 negative studies utilized self-reported measures of stress 
rather than objective measures such as inperson interviews; 
studies that assessed specific clearly operationalized stres-
sors, rather than generalized number of stressors, consistently 
find that the S allele moderates the association between child 
maltreatment and depression, most likely due to more robust 
internal validity; and studies that focused on a specific stres-
sor of childhood maltreatment rather than stressful or adverse 
life events, consistently demonstrated positive findings.5
Examining more complex interactions, Coplan et al in 
macaques27 and Ressler et al in humans28 tested the G × E 
interactions between 5-HTTLPR and corticotropin-releasing 
hormone polymorphism (CRHR1) on childhood abuse 
and depressive symptoms. Coplan et al reported that cor-
ticotropin-releasing hormone concentrations were elevated 
in macaques raised in a primate model of early-life stress 
specifically in S/S and S/L genotype groups.27 Ressler et al 
reported that the S allele in their study (n = 856) interacted 
with the CRHR1 haplotypes and child abuse that predicted 
current depressive symptoms. These researchers concluded 
that their data suggest that the G × E interactions predict 
depressive symptoms may be differentially sensitive to levels 
of childhood trauma.28
While the exact nature of the association between 5-HTT 
genotype and depression continues to be a complex area 
of research, what is established is that the 5-HTT geno-
type can significantly influence response to antidepressant 
medications. For example, a study was performed in China 
with 121 patients diagnosed with major depressive disorder 
and treated with the selective serotonin reuptake inhibitor 
(SSRI) fluoxetine (mean 29.4 ± 10.4 mg/day) demonstrated 
that subjects homozygous for the L allele had a significantly 
greater decrease in their Hamilton Depression Rating Scale 
(HAM-D) score than subjects who carried the S allele.29 
While decreases were significantly greater in L/L participants 
in the measures of total and core HAM-D scores, of note 
is that reductions in psychic anxiety and somatic anxiety 
were also significant, while differences in the measures 
of sleep, activity, and delusion were not.29 This group also 
demonstrated that participants with the L/L genotype were 
more likely to be responders, and noted that these results 
were consistent with earlier studies conducted in Western 
populations.30–32 Yu et al concluded that the 5-HTTLPR was 
responsible for 5.1% of variation in SSRI response and sug-
gested an additive effect with other polymorphisms, such as 
the tryptophan hydrolase (involved in 5-HT biosynthesis) 
polymorphism.29
A study performed in a Caucasian population comparing 
antidepressant response of L/S and L/L to S-homozygous 
variants demonstrated that carriers of the L allele (ie, L/L and 
L/S) showed a greater response to fluvoxamine 300 mg/day 
than S homozygotes.30 However, this result may also differ 
by ethnic population. For example, a study performed in 66 
Japanese patients with major depressive disorder reported 
that patients with the S allele were more responsive (though 
not significantly so) to 200 mg a day of fluvoxamine.31 
Additionally, in a study of 120 Korean patients with major 
depressive disorder (and 252 controls) who received flu-
oxetine or paroxetine similarly did not report that the L/L 
5-HTTLPR was associated with response to SSRIs, though 
it should be noted that, compared with European American 
populations, the allele frequency of S variant 5-HTTLPR in 
the Korean population, like the Japanese, was much higher.32 
Further studies of these discrepancies in a variety of ethnic 
populations are necessary.
A study of inpatients with the L/S genotype had a response 
to 40 mg daily of the SSRI paroxetine somewhere in between 
that of S and L homozygotes, suggesting a possible gene-
dose effect.33 By contrast, the 5-HTT genotype was shown 
to have no effect on treatment outcome in patients treated 
with the tricyclic antidepressant nortriptyline (plasma doses 
50–150 ng/mL), but L/L patients treated with paroxetine 
30 mg/day had significant reductions in HAM-D scores from 
baseline, suggesting that the genotype effect on antidepres-
sant response may be unique to treatment with SSRIs.34 
Additionally, the L/L genotype was associated with a 
quicker response to the SSRI paroxetine compared with 
S carriers,34 a finding confirmed with the SSRI sertraline 
(50–100 mg/day), in an elderly Caucasian sample (n = 206) 
suggesting perhaps a SSRI class-wide effect of genotype 
on speed of antidepressant response.35 On the other hand, 
Lewis et al in a European study of 258 patients taking cit-
alopram and 262 taking reboxetine and meeting the criteria 
for a depressive episode reported no evidence to support the 
5-HTTLPR polymorphism as a predictive tool to predict 
response to antidepressants in patients with depression.36
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Examining the association between 5-HTLPR and 
SSRI response, Huezo-Diaz et al demonstrated that gender 
moderated the outcome of treatment with escitalopram 
10–30 mg/day.37 The study yielded a result in the hypoth-
esized direction, in that participants with the S/S genotype 
who had received escitalopram had significantly poorer out-
comes compared with L carriers.37 When stratified by gender, 
the association was significant in men but not in women and 
the authors hypothesized that this gender effect was mediated 
by the affect of ovarian hormones on serotonergic function,37 
although ovarian hormones were not assessed directly in this 
sample (eg, before and after treatment with escitalopram). As 
a result of their research, Huezo-Diaz et al proposed that an 
additional polymorphism, single nucleotide polymorphism 
rs2020933 located in the first intron of the SLC6A4 gene,37 
and subsequent research by Keers et al38 examining the 
significant interaction between 5-HTTLPR and stressful 
life events, predicted a response to escitalopram, but not to 
nortriptyline, and may play significant roles in moderating 
and predicting response to SSRI antidepressants.
A meta-analysis performed by Serretti et al assessed the 
remission rate, response rate, and response within the first 
four-week period of treatment with SSRIs.39 In this meta-
analysis of 15 studies with 1435 patients reporting various 
types of depression (eg, major depressive disorder, bipolar 
disorder), patients with S/S alleles took longer to respond 
and were less likely to achieve remission. Pooled analysis 
of L/L and L/S genotypes versus the S/S genotype yielded 
a significant odds ratio (OR) for remission rate for the S/S 
genotype; while the analysis of the L/L genotype versus the 
L/S and S/S genotypes yielded significant OR for response 
rate and response within four weeks, confirming a significant 
association of the L variant of the 5-HTTLPR with a better 
response to SSRIs.39
Alternately, a more recent meta-analysis was performed 
to clarify the effect of 5-HTTLPR on SSRI response and 
rate of remission in 5408 patients with major depressive 
disorder across 28 studies.40 No statistically significant effect 
of transporter promoter length polymorphism on rates of 
antidepressant response was seen. While the authors reported 
a weak effect of biallelic polymorphism on remission, a 
number of factors, like publication bias or lack of reporting 
of the remission outcomes, were hypothesized as additional 
factors to consider.40
The results of studies assessing the association between 
5-HTTLPR and depression are inconsistent. Many research-
ers report an association between 5-HTTLPR and anti-
depressant response and that the homozygous L alleles 
confer a better response to SSRIs than the homozygous or 
heterozygous S alleles.29,30,33–35,37–39 While this finding, as 
determined by post hoc analyses, may represent a promising 
determinant for personalization of antidepressant therapy, 
it should be noted that the strength of this association may 
vary by population,31,32 and is not consistently reported.36,40 
Before a priori genotyping can become a reality, measure-
ment of the association and effect size of other genes affect-
ing antidepressant response is also required so as to form a 
complete genotypic picture of the patient. Additionally, there 
must be an effort to standardize assessments such that data 
and diagnoses can be meaningfully compared across studies. 
Also, more research is needed across cultural populations 
before concluding that the S allele, which is theorized to 
increase a carrier’s predisposition to depression, is associated 
with poorer response to SSRIs in only certain populations, 
certainly a finding which has significant implications for the 
future development of antidepressant medications.41
Suicidal behavior
Though only a proportion of patients diagnosed with major 
depressive disorder make a suicide attempt, this associa-
tion is independent of depression severity,42 leading to the 
hypothesis that there are other risk factors for suicidal 
behavior, including a genetic predisposition involving the 
5-HTTLPR.43 For example, Du et al provided evidence for 
this association, reporting that depressed suicide victims had 
a significantly higher frequency of the L allele than control 
subjects of the same ethnicity.43 The evidence also sug-
gests that depressed suicide victims had almost double the 
frequency of the L/L genotype than that of controls (48.6% 
versus 26.2%), yielding a significant OR of 2.1.44
However, in contrast, other studies report no direct or even 
contrary associations between 5-HTT genotypes and suicidal 
behavior. For example, while allele frequencies did not differ 
between suicidal inpatients and controls, inpatients who had 
the L/L genotype had significantly increased hopelessness 
and suicidal ideation.45 Moreover, though a meta-analysis 
of 12 studies (n = 2539) reported an association between 
5-HTT genotype and suicide, the S allele but not the L allele 
was positively associated with suicidal behavior.46 Notably, 
when the researchers included studies that were stratified by 
type of suicidal behavior, the association was attributable to 
studies investigating suicide attempters versus completers.46 
The heterogeneity of these findings therefore suggests that 
suicidal ideation, attempted suicide, and completed suicide 
may represent distinct yet overlapping phenotypes within 
the broader category of suicidal behavior.44
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Bipolar disorder
While the lifetime prevalence of bipolar disorder is estimated 
to be about 1%, relatives of patients with bipolar disorder 
have significantly greater susceptibility to the disorder.47 
 Specifically, monozygotic twins and first-degree relatives 
have a lifetime risk of 40%–70% and 5%–10%, respectively, 
versus a lifetime risk of  0.5%–1.5% in unrelated  individuals.47 
Candidate gene studies have primarily investigated the genes 
that code for the neurotransmitter systems targeted by phar-
maceutical agents employed in the management of bipolar 
disorder; consequently, 5-HTT has been implicated through 
its regulatory role in 5-HT neurotransmission.47
A meta-analysis of 23 studies assessed the association 
between 5-HTTLPR and bipolar disorder, and included 
both family and population-based studies.48 The S allele 
was significantly associated with increased susceptibility 
to bipolar disorder.48 A significant OR for another poly-
morphism, ie, the intron 2 variable numbers of tandem 
repeats (VNTR) polymorphism, was also reported (OR: 
1.12; 95% confidence interval [CI]: 1.02–1.22).48 These 
findings for both 5-HTTLPR and intron 2 VNTR were sup-
ported by others who reported small but significant OR of 
1.14 (95% CI: 1.03–1.26) and 1.18 (95% CI: 1.05–1.32), 
respectively.49 Given the heterogeneity of bipolar disorder, 
researchers44 have interpreted the small effect sizes as sug-
gestive of either a polygenic model for bipolar disorder 
susceptibility or a G × E  interaction similar to that proposed 
for  unipolar depression.7
Rotondo et al sought to determine if comorbid panic 
disorder had an effect on the association between patients 
with bipolar disorder and 5-HTTLPR genotype.50 While a 
significant increase in S allele frequency was discovered in 
all patients with bipolar disorder, grouping by the presence 
or absence of comorbid panic disorder implicated genetically 
distinct subtypes of bipolar disorder.50 Specifically, subjects 
with bipolar disorder but without comorbid panic disorder, 
had a significantly increased frequency of the S allele com-
pared with healthy subjects (P = 0.008), while patients with 
comorbid bipolar disorder and panic disorder did not have 
any significant difference in allele frequency compared with 
healthy controls.50 This suggests that the absence or presence 
of comorbid panic disorder in patients with bipolar disorder 
may represent unique bipolar disorder subtypes with different 
genetic susceptibilities.50
Some patients with bipolar disorder taking antidepres-
sants without a concurrent mood stabilizer can experience 
antidepressant-induced mania;51 this effect is sometimes 
referred to as type 3 bipolar disorder.51 Consequently, 
a genotype-mediated effect on antidepressant response may 
place individuals at a higher risk for this adverse event. As 
discussed in the section on depression, studies including 
patients with bipolar disorder have demonstrated that the 
5-HTT genotype can affect SSRI treatment outcomes, as 
measured by change on depression rating scales.38 Hence, 
determination of genotype effect on risk of antidepressant-
induced mania is critical to management of bipolar disorder. 
However, while one group52 reported a significant association 
between the S allele and manic or hypomanic episodes in 
bipolar disorder patients treated with proserotonergic antide-
pressants (P , 0.001), other studies have failed to find any 
significant association.53,54
Post-traumatic stress disorder
Although post-traumatic stress disorder inherently requires 
exposure to a traumatic event, not all individuals who 
experience such an event develop DSM-IV-TR-diagnosed 
post-traumatic stress disorder.55–57 This is evident in the 
stark contrast between the 40%–80% lifetime prevalence 
of exposure to traumatic events and the lifetime incidence 
of post-traumatic stress disorder in one of 12 adults.52–54 
This distinction suggests that individuals who develop 
post- traumatic stress disorder in response to exposure to a 
traumatic event may have a predisposing factor not present 
in perhaps more resilient unaffected individuals.
In order to delineate such predisposing factors, the effect 
of 5-HTTLPR on susceptibility to post-traumatic stress 
disorder was assessed.55 Patients with post-traumatic stress 
disorder had a significantly higher frequency of the S/S geno-
type compared with unaffected controls.55 While this study 
demonstrated a significant association between 5-HTTLPR 
genotype and susceptibility to post-traumatic stress disorder, 
unaffected controls did not have a history of trauma exposure, 
and consequently, assessment of 5-HTTLPR as a predispos-
ing factor was not possible. However, in a more recent study, 
Wang et al confirmed that the S/S genotype was a significant 
predisposing factor (P = 0.03) for the development of post-
traumatic stress disorder in a sample of 388 combat veterans 
after trauma exposure.56
Similar to the G × E effect proposed for depression,7 
the influence of a G × E effect on the development and 
treatment of post-traumatic stress disorder in individuals 
exposed to traumatic events as a child or adult have also 
been examined. For example, Xie et al57 demonstrated that 
while the 5-HTTLPR genotype alone was not significantly 
associated with post-traumatic stress disorder, S carriers 
were at an increased risk of post-traumatic stress disorder in 
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response to trauma as a child and as an adult.57 Moreover, 
the effect size was even greater for individuals with post-
traumatic stress disorder who experienced traumatic events 
both as a child and as an adult.57 In addition, the number of 
traumatic life events, especially as a child, was also seen to 
increase the predisposition to post-traumatic stress disorder 
in S carriers.53 These results were also confirmed in a study 
of 5-HTTLPR, childhood trauma, and cognition in patients 
with psychotic disorders.58 There was a significant interac-
tion across cognitive domains, such that S/S carriers exposed 
to high levels of childhood trauma had significantly poorer 
cognitive functioning than all other groups. Additionally, 
consistent with the research on depression, in a study of 330 
outpatients diagnosed with post-traumatic stress disorder and 
treated with sertraline 100 mg/day, Mushtaq et al reported a 
significant response to sertraline treatment for the group with 
the L/L allele only.59 As also noted for depression,29,30,33,34 
there was a nonresponse to SSRI treatment for those with 
either the S/S or S/L alleles.
However, other researchers have indeed reported conflict-
ing results. For example, Grabe et al reported a significant 
association between the high activity L
A
-homozygous geno-
type and post-traumatic stress disorder, and noted a gene-
dose effect as the crude proportion of post-traumatic stress 
disorder increased in the study groups from 2% (zero), 4% 
(one), to 6% (two) L
A
 alleles.60 Moreover, no association was 
reported for the low-activity L
G
 allele. In addition, among 
L
A
 carriers, the increased post-traumatic stress disorder risk 
was reported to be even greater in subjects who experienced 
three or more traumatic events (12.8%) than those who had 
not (3.9%), suggesting an interaction between the L
A
 allele 
and number of traumatic life events.57 While these authors60 
note that the results are inconsistent with some previous 
studies,55,61 they also suggest that low statistical power and 
a failure to differentiate the L allele subtypes (ie, L
A
 and L
G
) 
may explain the varying results of these other studies.
Alcohol dependence
Alcohol dependence has 50%–60% heritability, and it is 
estimated that as much as 40% of variance in alcohol depen-
dence may be attributable to genetic factors.62–64 Given the 
interplay of the 5-HT and dopamine systems and its role in 
novelty seeking and reward, 5-HT regulatory genes have been 
suggested as candidates for vulnerability to alcohol depen-
dence and, of these, 5-HTTLPR has received considerable 
attention.64–66 While most studies demonstrate an association 
between 5-HTTLPR and alcohol dependence, the association 
with specific alleles is inconsistent, varying based on  alcohol 
subtype, type of drinking behavior, ethnicity, comorbid 
diagnoses, or age of onset.
For example, in a study of inpatients with alcohol depen-
dence in Korea, the association between the 5-HTTLPR 
and alcohol dependence was assessed.64 L carriers had a 
significantly increased risk of alcohol dependence and the 
researchers also noted a gene-dose effect. The gene-dose 
effect suggested that inpatients with L/L alleles had an 
even greater risk of alcoholism compared with those hav-
ing heterozygous variants. In addition, it was reported that 
patients with a family history of alcohol dependence had a 
significantly higher frequency of the L allele and L-carrying 
patients with alcohol dependence had a significantly younger 
age of onset.64 Others have also demonstrated that reduced 
functional 5-HTT uptake in L carriers, not S/S carriers, is due 
to the effect of alcohol on 5-HTT gene expression and that 
5-HTT expression varies with current and lifetime alcohol 
consumption in people with the L genotype alone, resulting 
in more severe and chronic drinking.65
In 34 Hispanic individuals with alcohol dependence, a 
G × E interaction hypothesis was tested, ie, those with the L/L 
or L/S genotype would have higher craving for alcohol due to 
lower 5-HT neurotransmission than those with the S/S geno-
type.67 Also hypothesized was that acute peripheral depletion 
of tryptophan, while reducing 5-HT function, at the same 
time may decrease autoinhibition of 5-HT neuronal firing, 
transiently increasing 5-HT neurotransmission, leading to 
lowered alcohol craving for individuals with the L genotype. 
And while a significant main effect was reported of genotype 
and alcohol cue, as well as an interaction among genotype, 
age of onset of problem drinking, and tryptophan depletion, 
L carriers reported higher craving for alcohol. This effect 
decreased as hypothesized under tryptophan depletion.64 In 
addition, craving in L carriers also increased, with an earlier 
age of onset of problem drinking, an effect opposite to that 
reported by individuals with the S/S genotype.67
While the association between alcohol dependence and 
5-HTTLPR is significant, it must also be kept in mind that 
5-HTTLPR frequencies are also known to vary dramatically 
with ethnicity,64 and a meta-analysis with a broader ethnic 
sample yielded conflicting results.66 Notably, a meta-analysis 
of 22 studies (n = 8050) was conducted to investigate the 
association between 5-HTTLPR and a clinical diagnosis 
of alcohol dependence. A significant association between 
alcohol dependence and the S allele was reported, with an 
even greater effect seen in those with the S/S genotype. 
 However, a possible publication bias was noted (P , 0.05), 
with a greater number of studies reporting no association 
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being published in recent years. It was also reported that the 
study size influenced the reported effect size, with larger 
studies finding relatively smaller effects.66
Other studies that have examined the relationship between 
alcohol dependence and 5-HTTLPR, have discovered the 
association to be the strongest among alcohol-dependent 
individuals with co-occurring diagnoses, age of onset, or 
drinking subtype. For example, a study of heavy drinking 
young adults by Tartter and Ray68 demonstrated that heavier 
alcohol use was associated with depressive symptoms in 
L/L homozygotes but not among S carriers. These results 
also indicated a main effect of 5-HTTLPR genotype such 
that L allele homozygotes had significantly more alcohol 
problems and more drinks consumed over a 30-day period 
than S allele carriers. This study offers support for the L 
allele as a risk for alcohol abuse problems when depressive 
symptoms are present. However, these results contrast with 
those reported by Feinn et al from a meta-analysis of data 
from 17 studies consisting of 3489 individuals with alcohol 
dependence and 2325 controls. In this study, the frequency 
of the S allele was significantly associated with alcohol 
dependence.69  Additionally, the association was even greater 
among individuals with alcohol dependence and either a 
comorbid psychiatric condition or an early-onset or more 
severe subtype of alcohol dependence.69
In recent research, the frequency of the S allele was 
reported to be significantly increased in patients with alco-
hol dependence and comorbid drug dependence.70 Notably, 
no significant association was reported for patients with 
 alcohol dependence alone.66 Additionally, though no sig-
nificant  difference in allele frequencies between patients 
with  alcohol dependence and controls was reported, the 
frequency of the S-homozygous genotype was significantly 
greater in  binge-drinking patients with alcohol dependence.8 
This  f inding was similarly reported by others65,71 who 
 demonstrated that S/S subjects tended to binge drink and were 
younger than L/L subjects, together suggesting a subgroup 
of patients with alcohol dependence genetically predisposed 
to binging behavior.8,65,72
While the variation in results regarding the association 
between 5-HTTLPR and alcohol dependence likely reflects 
the underlying heterogeneity of alcohol dependence itself, 
the 5-HTTLPR genotype has been investigated and used 
to target pharmacotherapy for relatively homogenous sub-
groups. It was proposed for example that genotypic differ-
ences exist between two subtypes of patients with alcohol 
dependence, ie, type A alcoholics with late-onset alcohol-
ism starting after 25 years of age and type B alcoholics 
with  early-onset  alcoholism starting at 25 years of age or 
younger.3,72–74 Among patients with alcohol dependence, 
the S/S and S/L genotypes have been associated with 
late-onset alcoholism, few pathological problems, few 
drinking-related problems, and childhood risk factors. The 
L/L genotype, on the other hand, has been associated with 
early-onset alcoholism, more severe psychopathology, 
antisocial and impulsive tendencies, childhood risk factors, 
and significant problems with alcohol. The neurobiological 
differences between these two subtypes may have significant 
implications for alcohol dependence pharmacotherapy.73,74
Results of clinical trials using SSRIs for the treatment of 
alcohol dependence in a heterogeneous group of alcoholics 
have produced mixed results. For example, among patients 
with alcohol dependence treated with fluoxetine 60 mg/day, 
type A alcoholics did not differ significantly from the placebo 
group in measures of alcohol consumption while type B 
alcoholics (who have typically an early onset of alcoholism) 
had worse drinking outcomes.75 This finding of increased 
alcohol consumption with SSRIs in early-onset alcoholism 
was confirmed.72 However, this study also demonstrated 
that in late-onset alcoholism, treatment with sertraline 
200 mg/day was associated with fewer drinking days and 
a greater likelihood of continuous abstinence (P = 0.01 and 
P = 0.004, respectively). In contrast with patients having ear-
ly-onset alcoholism, in patients with late-onset alcoholism, 
who have predominantly the S/S or S/L genotypes, SSRIs 
are thought to facilitate serotonergic neurotransmission and 
inhibition of dopamine, thereby decreasing the positive rein-
forcement and reward from acute alcohol consumption.3,68,72 
Thus, these results may suggest that, among patients with 
alcohol dependence, patients with late-onset alcoholism 
may exhibit a favorable response to treatment with SSRIs, 
while patients with early-onset alcoholism may increase 
alcohol consumption.
To pursue this line of research further, Kranzler et al77 
examined the moderating effects of the triallelic 5-HTTLPR 
in a 12-week, parallel-group, placebo-controlled trial admin-
istering up to 200 mg of sertraline (n = 63) or placebo (n = 71) 
daily to 134 patients with alcohol dependence and compared 
the effects in late-onset alcoholics versus  early-onset alco-
holics. Kranzler et al augmented their model to test whether 
the effect of treatment varied over time and by 5-HTTLPR 
genotype. The L
G
 and S alleles were grouped together as 
S′ (the lower expression allele) and the L
A
 allele was des-
ignated as L′ (the higher expression allele).  Analyses for 
this study included main and interaction effects of medica-
tion group, age at onset of alcohol dependence (#25 years 
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versus .25 years), and 5-HTT genotype on drinking out-
comes. For L′/L′ patients alone, the effects of medication 
group varied as a function of age of onset, because at the end 
of treatment, late-onset alcoholics with L′/L′ alleles reported 
fewer drinking and heavy drinking days when treated with 
sertraline. Early-onset alcoholics on the other hand treated 
with sertraline, were significantly more likely to drink on a 
given day than those treated with placebo. While there was 
no difference on heavy drinking days between sertraline-
treated and placebo-treated L′/L′ late-onset alcoholics, early-
onset alcoholics treated with sertraline were significantly 
more likely than placebo-treated early-onset alcoholics to 
drink heavily on a given day. Hence, this was the first study 
in patients with alcohol dependence in whom analyses 
were performed by triallele, and demonstrated that while 
a certain subtype of patients with alcohol dependence may 
benefit (L′/L′), use of SSRIs in a heterogeneous population 
(ie, early-onset alcoholics with L′/L′ alleles) must be done 
with caution, if at all.75–77 If confirmed, this study represents 
a clinically relevant example of pharmacogenetics based on 
the 5-HTTLPR genotype, given the possibility of identifying 
the best responders to a medication, as well as those patients 
who should not receive that medication.
In contrast with late-onset alcoholism in which relatively 
normal serotonergic neurotransmission is maintained, the L/L 
genotype associated with early-onset alcoholism is thought 
to result in reduced intersynaptic 5-HT, thereby inducing a 
compensatory upregulation of the 5-HT
3
 receptor.3,68,72 In 
response to acute alcohol consumption, upregulation of the 
5-HT
3
 receptor is hypothesized to result in an increase in dop-
amine release in the nucleus accumbens,79 thereby increasing 
the positive reinforcement and reward from alcohol use in 
these individuals. Furthermore, a significant association 
between the L/L genotype and compulsive alcohol craving 
in patients with alcohol dependence has also been reported.80 
Studies have suggested that the 5-HT
3
 antagonist ondansetron 
at 4 µg/kg twice a day may be a particularly effective treat-
ment option for alcohol dependence among patients with 
early-onset alcoholism.69 Johnson et al reported that treat-
ment with ondansetron resulted in a significant increase in 
the number and percentage of days abstinent in patients with 
early-onset alcoholism but not late-onset alcoholism.81
These results with ondansetron in early-onset alcoholic-
L/L genotype patients are clouded by findings that among 
non-treatment-seeking alcohol-dependent subjects homozy-
gous for the L allele, those receiving ondansetron reported 
significantly fewer drinks per drinking day than S carriers 
during the 7 days prior to an alcohol drinking session.72 
 Further, this laboratory study was confirmed in 283 patients 
with alcohol dependence who were randomized by 5-HT-
TLPR genotype, not age of onset, with additional genotyp-
ing for another functional single nucleotide polymorphism 
in the 3′-untranslated region, rs1042173, in a double-blind, 
placebo-controlled trial.82 Subjects received ondansetron or 
placebo for 11 weeks plus standardized cognitive behavioral 
therapy. The study reported that L/L patients who received 
ondansetron 4 µg/kg twice a day had significantly fewer 
mean drinks per drinking day and a higher percentage of days 
abstinent compared with the placebo group.79 In ondansetron 
recipients, drinks per drinking day was significantly lower 
and percentage of days abstinent significantly higher in L/L 
versus S carriers.82 Ondansetron L-homozygous subjects 
also reported significantly fewer drinks per drinking day and 
greater percentage of days abstinent than all other genotype 
and treatment groups combined.82 For both drinks per drink-
ing day and percentage of days abstinent, 5-HTTLPR and 
rs1042173 variants interacted significantly.82 Patients receiv-
ing ondansetron who had LL/TT alleles reported significantly 
fewer drinks per drinking day and a greater percentage of 
days abstinent than all other genotype and treatment groups 
combined.82 Thus, given the significant differences in 
treatment efficacy between sertraline and ondansetron and 
between subgroups, determination of alcoholism typology 
and genotype is becoming more valuable to understand-
ing the potential for more effective treatment matching for 
alcohol dependence.
Nicotine dependence
Twin studies have suggested a genetic influence in the 
development of smoking behaviors such as nicotine depen-
dence and especially smoking initiation.83 Moreover, the 
heritability of nicotine dependence and of smoking initia-
tion is estimated to be 62% and 47%–76%, respectively.84,85 
The serotonergic system has been suggested to play a role 
in smoking behavior, because acute nicotine administration 
has been shown to increase release of 5-HT in the brain, and 
chronic nicotine use depletes 5-HT stores.85 Further, since 
antidepressants have demonstrated efficacy in smoking 
cessation,86 it was theorized that 5-HTTLPR may influence 
smoking behavior.85,87
Kremer et al, investigating the influence of 5-HTT 
genotype on smoking behavior, reported a significantly 
greater frequency of the L-allele with the 12-repeat VNTR, 
a polymorphism also known to increase transcriptional activ-
ity of the gene, in both current and past smokers compared 
with nonsmoker controls.87 In addition, this association was 
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significantly strengthened using combined current and past 
smokers compared with nonsmokers, yielding an estimated 
risk for these polymorphisms of 1.37 (95% CI: 1.17–1.61).87 
The authors theorized that low serotonergic tone associ-
ated with increased activity of the L allele may result in an 
increased sensitivity to 5-HT release, and resulting dopamine 
release in the nucleus accumbens, from acute nicotine use.87 
Also, after smoking initiation, L carriers are thought to be at 
an increased risk of developing dependence due to the further 
reduction in 5-HT levels with chronic nicotine use.87
In an open-label randomized clinical trial of transdermal 
patch versus nasal spray nicotine replacement therapy for 
smoking cessation in 397 smokers.88 To assess smoking 
status, telephone interviews were conducted at the end of 
treatment and at 6-month follow-up. Munafo et al predicted 
that possession of one or more copies of the S allele of 
the 5-HTTLPR polymorphism would be associated with a 
reduced likelihood of successful smoking cessation. They 
also explored the possibility that nicotine replacement 
therapy delivered via nasal spray may be more effective 
than nicotine replacement therapy delivered via transder-
mal patch in smokers with one or more copies of the S 
allele. The main effect of the 5-HTTLPR genotype was not 
associated with abstinence at either the end of treatment 
or at 6-month follow-up, and there was no evidence for a 
genotype × treatment interaction effect. All other effects 
were also nonsignificant, although the effect of nicotine 
dependence score on abstinence at 6-month follow-up 
approached statistical significance (P = 0.07). These results 
provide no support for an association between 5-HTTLPR 
genotype and smoking cessation in response to nicotine 
replacement therapy.88
Attention deficit hyperactivity disorder
Twin and adoption studies demonstrate a significant genetic 
influence in the development of attention deficit hyperactiv-
ity disorder (ADHD) and the heritability is estimated to be 
76%.89 While the serotonergic system is not targeted directly 
by stimulant drugs efficacious in the treatment of ADHD, it 
is thought that pharmacological alteration of the dopamine 
system by these drugs might influence 5-HT transmission 
projecting downstream.90 Moreover, some have hypothesized 
that SSRIs might be useful in the treatment of ADHD patients 
who do not respond to traditional pharmacotherapy or those 
with comorbid psychiatric disorders.91 Hence, it is theorized 
that the serotonergic system may play a role in mediating the 
effects of ADHD drugs and it has been suggested that 5-HTT 
genotype may affect predisposition to this disorder.90–92
In a study that assessed the association between 5-HTT 
genotype and hyperkinetic disorder with and without conduct 
disorder, the frequency of the L-homozygous genotype was 
significantly increased in patients with hyperkinetic disorder 
both with and without conduct disorder (P = 0.004).91 In 
addition, patients with the L/L genotype scored significantly 
higher than patients with the S/L and L/L genotypes on the 
Wender Utah Rating Scale (WURS, an instrument used to 
measure ADHD-related symptoms) for the diagnosis of 
ADHD.93 Moreover, among participants who scored above 
100 on the WURS, the frequency of the L allele was signifi-
cantly increased.93 In addition, another study demonstrated 
that the frequency of the S-homozygous genotype was sig-
nificantly lower in patients with ADHD than in controls.94 
Furthermore, a pooled OR for the L allele of 1.31 (95% CI: 
1.09–1.59) was reported for combined studies of the associa-
tion between 5-HTTLPR and ADHD.92
Assuming that the serotonergic system is involved in the 
response to stimulant drugs used to treat ADHD, the influence 
of 5-HTT genotype on response to methylphenidate 0.5 mg/
kg/day in children meeting DSM-IV diagnostic criteria for 
ADHD was examined by Thaker et al.90 While L
A
 carriers 
responded significantly better to methylphenidate than pla-
cebo, patients without a L 
A
 allele did not exhibit a signifi-
cantly better medication response compared with placebo.90 
In addition, patients without a L
A
 allele demonstrated a 
significant improvement in symptoms in response to placebo 
compared with patients with one L
A
 allele.90 Thus, patients 
with the lower expressing L
G
 alleles and S alleles exhibited a 
significant improvement in symptoms in response to placebo 
and did not obtain additional benefit from methylphenidate, 
while L
A 
 carriers had minimal response to placebo and 
improved significantly with methylphenidate.90
Conclusion
Classification of the genes responsible for heritable com-
ponents of various psychiatric disorders is crucial to the 
advancement of our understanding of the underlying neurobi-
ology and pathology of complex psychiatric diseases. Studies 
of the 5-HTTLPR polymorphism in psychiatry demonstrate 
a significant association with several disorders, with the S 
allele being the “risk allele” for numerous psychiatric dis-
orders, putatively due to decreased transcriptional activity. 
The S allele may be associated with heightened amygdala 
response, anxiety-related personality traits, major depressive 
disorder, attempted suicide, and bipolar disorder. In contrast, 
the increased transcriptional activity of the L allele has been 
associated with completed suicide, nicotine dependence, 
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and ADHD. Meanwhile, for some disorders, such as post-
traumatic stress disorder, the association has not yet been 
fully characterized, and for other disorders, such as alcohol 
dependence, the association appears to vary with alcohol sub-
type. Also, in conditions such as major depressive disorder, 
alcohol dependence, ADHD, and possibly bipolar disorder, 
the 5-HTTLPR polymorphism has generally but incon-
clusively been shown to have important pharmacotherapy 
implications, particularly in certain subgroups.
The great difficulty in transferring these results to useful 
pharmacotherapeutic approaches is due to the often incon-
sistent and conflicting associations between 5-HTTLPR 
alleles and outcomes. Most but not all data appear to show 
that Caucasian individuals with major depressive disorder, 
particularly those with L alleles, appear to respond faster to 
treatment with SSRIs, but not tricyclic antidepressants, and 
that individuals with post-traumatic stress disorder and L 
alleles also respond to treatment with an SSRI.
An almost universal problem with studies on the associa-
tion of the 5-HTTLPR is a lack of statistical power to detect 
what may be a relatively small effect, though it appears that 
methodologically sound statistical techniques can help to 
overcome this problem. Moreover, it appears probable that 
diseases as complex as psychiatric disorders have a complex 
genetic etiology, and are influenced by multiple genes and 
by interactions of genes within the environment. To this end, 
it seems that studies assessing the 5-HTTLPR as the only 
genetic factor contributing to the etiology of psychiatric dis-
orders will continue to be affected by statistically small effect 
sizes and limited replication. Because a polygenic model for 
the etiology of these disorders seems to be the case, future 
studies should attempt to assess the confluence of candidate 
genes together rather than individually. This will allow for 
determination of the relative effect sizes of genes, as well as 
prevent confounding from the heterogeneous distribution of 
other non-controlled candidate genes between arms of single 
gene association studies. In addition, many of the studies 
reviewed assessed the association of 5-HTTLPR as a bial-
lelic polymorphism and failed to account for the differential 
activity of the two distinct L-alleles. Because the L
G
 allele has 
transcriptional activity similar to the S allele, and only the 
L
A
 allele has been demonstrated to increase transcriptional 
activity, the L/L genotype reported in some studies may in 
actuality be L
G
/L
G
, and thus would have activity comparable 
with the S/S genotype, thereby confounding interpretation 
of the results. Thus, studies that treat the 5-HTTLPR as bial-
lelic may underestimate its effect at best or report a result 
opposite to what may be the true association. Discovery of 
the triallelic 5-HTTLPR alleles may help explain the con-
flicting results of many past association studies, while at the 
same time providing more meaningful data in the future. We 
therefore strongly encourage researchers in future studies to 
report results based on the 5′ HTTLPR triallele consistently 
and to report effect sizes as well.
Once results have been validated in large, well-powered 
meta-analytic studies that consider the triallelic 5-HTTLPR 
as part of a psychiatric haplotype, these findings may have 
important potential. For example, if a large effect size can be 
determined for a single gene or a combination of genes, this 
genetic panel may be used to screen individuals and allow 
for determination of susceptibility to various psychiatric 
disorders. Additionally, if particular G × E interactions exist, 
genetic screening may allow for targeted prophylactic treat-
ment after a stressful event in those at high risk. Moreover, 
genetically targeted treatment modalities in psychiatry may 
become a reality, allowing for the matching of the best drug 
for each unique individual.
In summary, there is considerable evidence that the 
5-HTTLPR polymorphism has significant implications in the 
etiology of many psychopathologies, and in some cases, even 
pharmacotherapy outcomes. However, the full influence of the 
5-HTTLPR polymorphism has not been completely elucidated 
nor confirmed. With the diffuse and varying functions of 5-HT, 
diseases and pharmacotherapies beyond those presented here 
may also be influenced by variation in the 5-HTTLPR.
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